Form 4: Eledon Pharmaceuticals Director Allan Kirk Acquires Stock Options and Restricted Stock Units

Director Allan Kirk of Eledon Pharmaceuticals acquired stock options for 30,870 shares and 3,430 restricted stock units on January 10, 2025.

Summary

• Allan Kirk, a director at Eledon Pharmaceuticals, acquired 30,870 stock options and 3,430 restricted stock units on January 10, 2025.
• The stock options have an exercise price of $4.04 per share and vest fully on January 10, 2026.
• The restricted stock units represent a contingent right to receive one share of common stock each, also vesting fully on January 10, 2026.
• Both the stock options and restricted stock units were acquired directly by Mr. Kirk.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option and restricted stock unit grants to a director. It is neither particularly positive nor negative, but indicates standard compensation practices.

Positives

• The acquisition of stock options and restricted stock units by a director suggests confidence in the company's future performance.
• The vesting schedule aligns the director's interests with the long-term success of the company.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are common forms of compensation for directors and executives in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors.
• The vesting period of one year is fairly standard for these types of grants.
• The exercise price of $4.04 for the stock options is a key detail, as it will determine the value of the options when they vest.

Stakeholder Impact

• The acquisition of stock options and restricted stock units by a director may be viewed positively by shareholders as it aligns the director's interests with the company's performance.
• The vesting schedule encourages the director to focus on long-term value creation.

Key Dates

Keywords

Eledon Pharmaceuticals, stock options, restricted stock units, insider trading, Allan Kirk, director, equity compensation, vesting